scorecardresearchSun Pharmaceutical Industries Share Price 831.30

Sun Pharmaceutical Industries

BSE: 524715 | NSE: SUNPHARMA | ISIN: INE044A01036 | SECTOR: Biotechnology & Drugs

831.30 0.50 (0.06%)

01 Jul 2022, 05:06 (IST)
  • Open

    834.40
  • High

    834.40
  • Low

    825.05
  • Prev Close

    830.80
  • P/E

    -
  • Median P/E

    -
  • P/B

    -
  • Median P/B

    -
  • Market Cap

    -
  • Volume

    10.63K
  • Vol. (20 day Avg.)

    0
  • PEG

    -
831.3
  • 825.05
  • Intraday
  • 834.40
831.3
  • 664.10
  • 52 Wk H/L
  • 966.90
831.3
  • 747.75
  • DPR
  • 913.85

Key Metrics

- Mkt. Cap.

V

Volatility %

Market Sentiment

  • Neutral
B

Beta -

Genie Says

Influencer Count

35

Financials

  • Actuals
  • Forecasted

Revenue vs. Profit Trend

No Chart data available

Peer Comparison

  • Price Comparison
  • Ratios Comparison
No data available
CompanyLatest Price
Change (% Chg)
52 Week
High
52 Week
Low
Market Cap.
(Cr)

Events

  • Dividends
  • Bonus
  • Splits
  • Rights
  • Board Meetings
  • Annual General Meetings

Ex-Dividend

Div Value

Description

    Simple Moving Averages

    DaysBSENSE

    Sun Pharmaceutical Industries is trading higher than 5 day, 20 day, 100 day and 200 day moving averages.

    Company Description

    • Large Cap
    • Automobiles
    • BSE

      524715
    • NSE

      SUNPHARMA
    • ISIN

      INE044A01036

    Sun Pharmaceutical Industries Limited is a specialty generic pharmaceutical company. The Company is engaged in the business of manufacturing, developing and marketing a range of generic formulations. It produces a portfolio of generic and specialty medicines targeting a spectrum of chronic and acute treatments. The Company’s product portfolio includes generics, branded generics, specialty, over the counter (OTC)/consumer healthcare products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and intermediates. Its OTC brands includes Faringosept , Revital, and Volini. The Company offers its products in variety of dosage forms, such as tablets, capsules, sprays, injectables, inhalers, ointments, creams and liquids. Its portfolio of specialty products, branded generics are available across 100 countries. The Company operates manufacturing sites across 6 continents.

    Company Officers

    • C. S. Muralidharan

      Chief Financial Officer
    • Uday Baldota

      Chief Executive Officer - Taro Pharmaceutical Industries Limited
    • Abhay Gandhi

      Chief Executive Officer, North America
    • Kirti Ganorkar

      Chief Executive Officer - India Business
    • Anilkumar Jain

      Chief Executive Officer - API Business
    • Jila Breeze

      Executive Vice President, Global Head - Quality
    • Pradeep Sanghvi

      Executive Vice President, Head - Research and Development, US
    • Aalok Shanghvi

      Executive Vice President, Head - Emerging Markets, Head - Global Generics, Research and Development, Business Development
    • Davinder Singh

      Executive Vice President - Sun Global Operations
    • Sapna Purohit

      Senior Vice President, Head of Human Resources